Taken together, our study not only identified JOSD2 as an important tumor-promoting factor that inhibits LKB1 kinase activity through deubiquitination of LKB1 in NSCLC, but also provided a potential therapeutic strategy in treating NSCLC patients by targeting JOSD2 with inhibitors. The gene discussed is JOSD2; the disease is non-small cell lung carcinoma.